Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber Trial.

ABSTRACT:

Purpose

The primary objective was to assess the acute efficacy of 0.25% reproxalap ophthalmic solution versus vehicle in patients with dry eye disease.

Design

This was a vehicle-controlled, randomized-sequence, double-masked, 2-period crossover trial.

Participants and controls

Sixty-three patients with dry eye disease were treated with reproxalap or vehicle in 2 treatment periods.

Methods

For each treatment period, patients were treated 4 times for 1 day, followed the next day by 1 dose before and 1 dose during a 90-minute dry eye chamber. Washout between treatment periods was 7 to 14 days.

Main outcome measures

The primary endpoints were ocular redness during the chamber and Schirmer test 10 minutes after the fourth dose on the prechamber day. The key s

SUBMITTER: Garg S 

PROVIDER: S-EPMC12553042 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature